Below is the commentary by Dr. Antonarakis upon the release of the most recent OS results from the SPARTAN trial of apalutamide in nmCRPC. Great results indeed! But what of those who are not yet castrate resistant?
However, note the last sentence (highlighted). An important unanswered question indeed. Should it be guided by PSADT or what?
practiceupdate.com/c/106535...
Emmanuel S Antonarakis MD:
"This study represents the mature analysis of overall survival from the SPARTAN study, a randomized trial of apalutamide versus placebo for nonmetastatic CRPC. The current analysis shows that, in addition to improving metastasis-free survival, there are now compelling data for an overall survival improvement using apalutamide for CRPC patients before the onset of metastatic disease. Taken together with the results of the PROSPER trial (enzalutamide vs placebo) and the ARAMIS trial (darolutamide vs placebo), both of which also showed a survival advantage with the use of novel antiandrogen therapy in the nonmetastatic CRPC setting, there is now substantial evidence of significant clinical benefit when using all three agents before the onset of metastatic disease. However, the question that is not answered by any of these trials is whether androgen-deprivation therapy should be started in the first place for nonmetastatic biochemically recurrent prostate cancers or what triggers should be used to decide when to start androgen-deprivation therapy in biochemically recurrent patients."
FDA Approves Darolutamide Plus Docetaxel for Metastatic Hormone-Sensitive Prostate Cancer
When to start ADT for metastatic disease
LATITUDE - Final Analysis
Immediate vs Deferred Treatment of BCR after primary and adjuvant therapies. ADT, now or later?
When to start ADT/RT given pandemic risks
